361 Capital’s Ligand Pharmaceuticals LGND Stock Holding History

361 Capital’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-27,270	Closed	-$1.69M	–	367
2019 Q3	$1.69M	Sell	27,270 -622	-2%	-$39.1K	0.31%	164
2019 Q2	$1.99M	Sell	27,892 -1,908	-6%	-$141K	0.35%	156
2019 Q1	$2.34M	Buy	+29,800	New	+$2.26M	0.41%	140
2018 Q4	–	Sell	-10,948	Closed	-$1.88M	–	362
2018 Q3	$1.88M	Sell	10,948 -3,367	-24%	-$508K	0.41%	77
2018 Q2	$1.85M	Sell	14,315 -2,936	-17%	-$328K	0.42%	58
2018 Q1	$1.78M	Buy	+17,251	New	+$1.71M	0.44%	52
2017 Q4	–	Sell	-24,710	Closed	-$2.1M	–	273
2017 Q3	$2.1M	Buy	+24,710	New	+$1.96M	0.4%	126
2016 Q1	–	Sell	-1,090	Closed	-$74K	–	126
2015 Q4	$74K	Buy	+1,090	New	+$67.3K	0.61%	48

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

361 Capital's LGND Position: Q4 2019 in Review

361 Capital sold out of Ligand Pharmaceuticals (LGND) in Q4 2019, closing a stake of 27,270 shares — an estimated $1.69M sold.

361 Capital first reported a position in LGND in Q4 2015 and held it in 8 quarters. The position peaked at $2.34M in Q1 2019. 266 funds tracked by Wall St. Rank hold LGND as of Q4 2019.

361 Capital reported no remaining Ligand Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
361 Capital sold 27,270 Ligand Pharmaceuticals shares in Q4 2019, an estimated $1.69M.
361 Capital first reported a position in Ligand Pharmaceuticals in Q4 2015 and held it in 8 quarters.
361 Capital's Ligand Pharmaceuticals position peaked at $2.34M in Q1 2019.
266 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2019.

Based on 361 Capital's 13F filing for Q4 2019, filed 13 Feb 2020.